Trial Profile
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib and Paclitaxel vs Herceptin and Paclitaxel With Sequential and Synchronous Anthracycline
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Paclitaxel; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 24 Mar 2017 New trial record